The protective role of curcumin in cardiovascular diseases

International Journal of Cardiology

Volumn 133, Issue 2, 2009, Pages 145-151

  Wongcharoen, Wanwarang ^a   Phrommintikul, Arintaya ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cardiovascular disease; Curcumin; Herbal medicine

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CHOLESTEROL; CURCUMIN; DOXORUBICIN; HISTONE ACETYLTRANSFERASE; LIPID PEROXIDE; PROTEIN P300;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYSTIC FIBROSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ANTAGONISM; ENTERITIS; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; MEMBRANE STABILIZATION; NEOPLASM; NONHUMAN; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CURCUMIN; FIBRINOLYTIC AGENTS; HUMANS;

EID: 62049085133     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.01.073     Document Type: Review

References (67)

1. Kiuchi F., Goto Y., Sugimoto N., Akao N., Kondo K., and Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull (Tokyo) 41 9 (1993) 1640-1643
2. Goel A., Kunnumakkara A.B., and Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 75 4 (2008) 787-809
3. Aggarwal B.B., Kumar A., and Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23 1A (2003) 363-398
4. Deodhar S.D., Sethi R., and Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71 (1980) 632-634
5. Satoskar R.R., Shah S.J., and Shenoy S.G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24 12 (1986) 651-654
6. Holt P.R., Katz S., and Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50 11 (2005) 2191-2193
7. Shoskes D., Lapierre C., Cruz-Correa M., et al. Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 80 11 (2005) 1556-1559
8. Durgaprasad S., Pai C.G., Vasanthkumar, Alvres J.F., and Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122 4 (2005) 315-318
9. Ng T.P., Chiam P.C., Lee T., Chua H.C., Lim L., and Kua E.H. Curry consumption and cognitive function in the elderly. Am J Epidemiol 164 9 (2006) 898-906
10. Doroshow J.H. Doxorubicin-induced cardiac toxicity. N Engl J Med 324 12 (1991) 843-845
11. Keizer H.G., Pinedo H.M., Schuurhuis G.J., and Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47 2 (1990) 219-231
12. Nowak D., Pierscinski G., and Drzewoski J. Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free Radic Biol Med 19 5 (1995) 659-663
13. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124 3 (1998) 425-427
14. Daosukho C., Chen Y., Noel T., et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against adriamycin-induced cardiac injury. Free Radic Biol Med 42 12 (2007) 1818-1825
15. Marcu M.G., Jung Y.J., Lee S., et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2 2 (2006) 169-174
16. Farhangkhoee H., Khan Z.A., Kaur H., Xin X., Chen S., and Chakrabarti S. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther 111 2 (2006) 384-399
17. Stadler K., Jenei V., von Bolcshazy G., Somogyi A., and Jakus J. Increased nitric oxide levels as an early sign of premature aging in diabetes. Free Radic Biol Med 35 10 (2003) 1240-1251
18. Hattori R., Sase K., Eizawa H., et al. Structure and function of nitric oxide synthases. Int J Cardiol 47 1 Suppl (1994) S71-75
19. Farhangkhoee H., Khan Z.A., Mukherjee S., et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 35 12 (2003) 1439-1448
20. Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr 30 1 (2006) 45-51
21. Brouet I., and Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206 2 (1995) 533-540
22. Farhangkhoee H., Khan Z.A., Chen S., and Chakrabarti S. Differential effects of curcumin on vasoactive factors in the diabetic rat heart. Nutr Metab (Lond) 3 (2006) 27
23. Decker R.S., Poole A.R., Griffin E.E., Dingle J.T., and Wildenthal K. Altered distribution of lysosomal cathepsin D in ischemic myocardium. J Clin Invest 59 5 (1977) 911-921
24. Mathew S., Menon P.V., and Kurup P.A. Changes in glycoproteins in isoproterenol-induced myocardial infarction in rats. Indian J Biochem Biophys 19 1 (1982) 41-43
25. Takahashi S., Barry A.C., and Factor S.M. Collagen degradation in ischaemic rat hearts. Biochem J 265 1 (1990) 233-241
26. Ravichandran L.V., Puvanakrishnan R., and Joseph K.T. Influence of isoproterenol-induced myocardial infarction on certain glycohydrolases and cathepsins in rats. Biochem Med Metab Biol 45 1 (1991) 6-15
27. Srivastava R., and Srimal R.C. Modification of certain inflammation-induced biochemical changes by curcumin. Indian J Med Res 81 (1985) 215-223
28. Nirmala C., and Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159 2 (1996) 85-93
29. Nirmala C., and Puvanakrishnan R. Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem Pharmacol 51 1 (1996) 47-51
30. Winter C.A. Nonsteroid anti-inflammatory agents. Annu Rev Pharmacol 6 (1966) 157-174
31. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
32. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7 8 (2006) 589-600
33. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
34. Kolodziejczyk S.M., Wang L., Balazsi K., DeRepentigny Y., Kothary R., and Megeney L.A. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 9 20 (1999) 1203-1206
35. Paradis P., MacLellan W.R., Belaguli N.S., Schwartz R.J., and Schneider M.D. Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J Biol Chem 271 18 (1996) 10827-10833
36. Herzig T.C., Jobe S.M., Aoki H., et al. Angiotensin II type1a receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc Natl Acad Sci U S A 94 14 (1997) 7543-7548
37. Hasegawa K., Lee S.J., Jobe S.M., Markham B.E., and Kitsis R.N. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation 96 11 (1997) 3943-3953
38. Backs J., and Olson E.N. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 98 1 (2006) 15-24
39. Clayton A.L., Hazzalin C.A., and Mahadevan L.C. Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell 23 3 (2006) 289-296
40. Chan H.M., and La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114 Pt 13 (2001) 2363-2373
41. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., and Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387 6635 (1997) 823-827
42. Miyamoto S., Kawamura T., Morimoto T., et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 113 5 (2006) 679-690
43. Yao T.P., Oh S.P., Fuchs M., et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 3 (1998) 361-372
44. Gusterson R.J., Jazrawi E., Adcock I.M., and Latchman D.S. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 278 9 (2003) 6838-6847
45. Yanazume T., Hasegawa K., Morimoto T., et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 23 10 (2003) 3593-3606
46. Li H.L., Liu C., de Couto G., et al. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 118 3 (2008) 879-893
47. Morimoto T., Sunagawa Y., Kawamura T., et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118 3 (2008) 868-878
48. Yeh C.H., Chen T.P., Wu Y.C., Lin Y.M., and Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 125 1 (2005) 109-116
49. Shishodia S., Singh T., and Chaturvedi M.M. Modulation of transcription factors by curcumin. Adv Exp Med Biol 595 (2007) 127-148
50. Virani S.S., Polsani V.R., and Nambi V. Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 10 2 (2008) 164-170
51. Schoonderwoerd B.A., Smit M.D., Pen L., and Van Gelder I.C. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. Europace 10 6 (2008) 668-673
52. Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol 195 3 (2003) 373-382
53. Hancock W.W., Buelow R., Sayegh M.H., and Turka L.A. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 4 12 (1998) 1392-1396
54. Ishikawa K., Sugawara D., Wang X., et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice. Circ Res 88 5 (2001) 506-512
55. Motterlini R., Foresti R., Bassi R., and Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28 8 (2000) 1303-1312
56. Pae H.O., Jeong G.S., Jeong S.O., et al. Roles of heme oxygenase-1 in curcumin-induced growth inhibition in rat smooth muscle cells. Exp Mol Med 39 3 (2007) 267-277
57. Verjovski-Almeida S., Kurzmack M., and Inesi G. Partial reactions in the catalytic and transport cycle of sarcoplasmic reticulum ATPase. Biochemistry 17 23 (1978) 5006-5013
58. Logan-Smith M.J., Lockyer P.J., East J.M., and Lee A.G. Curcumin, a molecule that inhibits the Ca2+-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca2+. J Biol Chem 276 50 (2001) 46905-46911
59. Sumbilla C., Lewis D., Hammerschmidt T., and Inesi G. The slippage of the Ca2+ pump and its control by anions and curcumin in skeletal and cardiac sarcoplasmic reticulum. J Biol Chem 277 16 (2002) 13900-13906
60. Duvoix A., Blasius R., Delhalle S., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223 2 (2005) 181-190
61. Ramirez Bosca A., Soler A., Carrion-Gutierrez M.A., et al. An hydroalcoholic extract of Curcuma longa lowers the abnormally high values of human-plasma fibrinogen. Mech Ageing Dev 114 3 (2000) 207-210
62. Soni K.B., and Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36 4 (1992) 273-275
63. Huang H.C., Jan T.R., and Yeh S.F. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 221 2-3 (1992) 381-384
64. Cheng A.L., Hsu C.H., Lin J.K., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 4B (2001) 2895-2900
65. Srivastava R., Dikshit M., Srimal R.C., and Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb Res 40 3 (1985) 413-417
66. Phrommintikul A., and Chattipakorn N. Roles of cardiac ryanodine receptor in heart failure and sudden cardiac death. Int J Cardiol 112 2 (2006) 142-152
67. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150